Suppr超能文献

银杏叶提取物50mg分散片用于缺血性心脑血管疾病临床应用专家共识

[Expert consensus on clinical application of GBE50 Dispersible Tablets for ischemic cardiovascular and cerebrovascular diseases].

作者信息

Yang Wen-Ming, Wang Han, Sun Su-Lun, Zhang Yun-Ling, Chen Xiao-Hu, Lu Jian-Qi, Wu Bo-Shui, Sun Jian-Ning, Chen Wei, Tang Lu-Lu, Represented The Editorial Team

机构信息

the First Hospital Affiliated to Anhui University of Chinese Medicine Hefei 230031,China.

Dongzhimen Hospital,Beijing University of Chinese Medicine Beijing 100700,China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2022 Jan;47(2):301-305. doi: 10.19540/j.cnki.cjcmm.20210809.501.

Abstract

Ginkgo biloba Extract( GBE50) Dispersible Tablets is a new standardized prescription,which is widely used in the treatment of ischemic cardiovascular and cerebrovascular diseases. However,there are still many problems in its clinical application.Rational and safe use of GBE50 Dispersible Tablets is pivotal to the medication safety and clinical prognosis of patients. This consensus has been jointly formulated by clinical experts of traditional Chinese medicine and western medicine in cardiovascular and cerebrovascular diseases and followed the Manual for the Clinical Experts Consensus of Chinese Patent Medicine published by the China Association of Chinese Medicine. The present study identified clinical problems based on clinical investigation,searched the research papers according to PICO clinical problems,carried out evidence evaluation,classification,and recommendation by GRADE system,and reached the expert consensus with nominal group technique. The consensus combines evidence with expert experience. Sufficient evidence of clinical problems corresponds to " recommendations",while insufficient evidence to " suggestions". Safety issues of GBE50 Dispersible Tablets,such as indications,usage and dosage,and medication for special populations,are defined to improve clinical efficacy,promote rational medication,and reduce drug risks. This consensus needs to be revised based on emerging clinical issues and evidencebased updates in practical applications in the future.

摘要

银杏叶提取物(GBE50)分散片是一种新型的标准化制剂,广泛应用于缺血性心脑血管疾病的治疗。然而,其临床应用仍存在诸多问题。合理、安全地使用GBE50分散片对患者的用药安全及临床预后至关重要。本共识由心脑血管疾病领域的中西医临床专家共同制定,遵循中华中医药学会发布的《中成药临床专家共识撰写指导原则》。本研究通过临床调研确定临床问题,依据PICO临床问题检索研究文献,采用GRADE系统进行证据评价、分级及推荐,并运用名义组技术达成专家共识。该共识将证据与专家经验相结合。临床问题证据充分对应“推荐”,证据不足对应“建议”。明确GBE50分散片的适应证、用法用量、特殊人群用药等安全性问题,以提高临床疗效,促进合理用药,降低用药风险。本共识未来需根据新出现的临床问题及实际应用中的循证更新进行修订。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验